Aerovate Therapeutics (AVTE) Stock Forecast, Price & News

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Aerovate Therapeutics in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" AVTE shares.
View AVTE analyst ratings or view top-rated stocks.

3 Wall Street analysts have issued 12 month price targets for Aerovate Therapeutics' shares. Their AVTE share price forecasts range from $27.00 to $54.00. On average, they expect the company's share price to reach $39.00 in the next twelve months. This suggests a possible upside of 144.8% from the stock's current price.
View analysts price targets for AVTE or view top-rated stocks among Wall Street analysts.

Aerovate Therapeutics' stock was trading at $29.30 at the start of the year. Since then, AVTE stock has decreased by 45.6% and is now trading at $15.93.
View the best growth stocks for 2023 here.

Aerovate Therapeutics saw a decrease in short interest in the month of May. As of May 15th, there was short interest totaling 913,900 shares, a decrease of 5.3% from the April 30th total of 965,000 shares. Based on an average daily trading volume, of 72,700 shares, the days-to-cover ratio is presently 12.6 days. Approximately 5.9% of the shares of the stock are short sold.
View Aerovate Therapeutics' Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Monday, August 21st 2023.
View our AVTE earnings forecast.

Aerovate Therapeutics, Inc. (NASDAQ:AVTE) released its quarterly earnings data on Wednesday, March, 29th. The company reported ($0.61) EPS for the quarter, missing analysts' consensus estimates of ($0.58) by $0.03.

ETFs with the largest weight of Aerovate Therapeutics (NASDAQ:AVTE) stock in their portfolio include Invesco DWA SmallCap Momentum ETF (DWAS), ALPS Medical Breakthroughs ETF (SBIO),

(AVTE) raised $100 million in an IPO on Wednesday, June 30th 2021. The company issued 7,150,000 shares at $13.00-$15.00 per share.

Aerovate Therapeutics trades on the NASDAQ under the ticker symbol "AVTE."

Aerovate Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Atlas Venture Life Science Advisors LLC (8.22%), Baker BROS. Advisors LP (7.91%), Great Point Partners LLC (3.05%), BlackRock Inc. (2.42%), FMR LLC (2.30%) and Ghost Tree Capital LLC (0.81%). Insiders that own company stock include Benjamin T Dake, Cormorant Asset Management, Lp, George A Eldridge, Hunter Gillies, Marinus Verwijs, Ralph Niven and Timothy P Noyes.
View institutional ownership trends.

Shares of AVTE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of AVTE stock can currently be purchased for approximately $15.93.

Aerovate Therapeutics (NASDAQ:AVTE) has a market capitalization of $395.22 million. The company earns $-51,510,000.00 in net income (profit) each year or ($2.33) on an earnings per share basis.

The official website for the company is aerovatetx.com. The company can be reached via phone at 617-443-2400 or via email at ir@aerovatetx.com.